Interleukin-1β and Arrhythmogenic Cardiomyopathy
Author Information
Author(s): Penna Vinay R., Amrute Junedh M., Engel Morgan, Shiel Emily A., Farra Waleed, Cannon Elisa N., Leu-Turner Colleen, Ma Pan, Villanueva Ana, Shin Haewon, Parvathaneni Alekhya, Jager Joanna, Bueno-Beti Carlos, Asimaki Angeliki, Lavine Kory J., Saffitz Jeffrey E., Chelko Stephen P.
Primary Institution: Washington University in St. Louis School of Medicine
Hypothesis
Targeting IL-1β may improve outcomes for patients with arrhythmogenic cardiomyopathy (ACM).
Conclusion
Targeting interleukin-1beta produced mainly by inflammatory macrophages attenuates arrhythmogenic cardiomyopathy disease progression.
Supporting Evidence
- ACM affects 1 in 5000 people globally and is caused by mutations in cardiac desmosomal proteins.
- Inflammatory-fibrotic niches were identified in ACM samples, indicating a role for inflammation in disease progression.
- Blocking IL-1β in a mouse model of ACM improved cardiac function and reduced fibrosis.
Takeaway
This study found that a protein called IL-1β, which is made by certain immune cells, can make a heart disease called arrhythmogenic cardiomyopathy worse, but blocking it can help the heart work better.
Methodology
The study used single nucleus RNA sequencing and spatial transcriptomics on myocardial samples from patients with ACM and control donors.
Potential Biases
The study focused only on left ventricular samples, which may not represent the full spectrum of ACM pathology.
Limitations
The human samples were collected at advanced stages of disease, limiting insights into earlier disease stages.
Participant Demographics
6 patients with arrhythmogenic cardiomyopathy and 12 control donors.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website